Spotlight on Neurology

Credits: 1.00 CME / MOC
SMA Horizons: What Is in the Future of SMA Management?
Claudia A. Chiriboga, MD, MPH
The France Foundation

SMA Horizons: What Is in the Future of SMA Management?

Start

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Part II points
Released: December 1, 2020
Expires: November 30, 2021
60 minutes to complete

Accredited By

Target Audience

This activity is intended for multidisciplinary groups of clinicians including neuromuscular specialists, pediatric neurologists, general neurologists, pediatricians, medical geneticists, genetic counselors, and other health care providers who are involved in the management of spinal muscular atrophy (SMA).

Learning Objectives

Upon completion of this course, the participants should be able to:

  • Review pathology, genetics, and epidemiology of SMA
  • Explain the importance of genetic testing for SMA
  • Discuss newborn screening and its importance in early diagnosis of SMA
  • Evaluate new and emerging therapies for SMA

Activity Description

With 3 therapies available for spinal muscular atrophy (SMA), clinicians need education in the genetics, newborn screening, and the clinical trial data. In these short videos, learners can choose the area they need education and hear from the experts.

Agenda

  • Presentation of SMA
  • Genetics of SMA
  • SMA Type and SMN2 Copy Number
  • Prevalence and Natural History of SMA
  • Diagnostic and Screening Algorithm
  • Genetic Testing for SMA
  • SMA Carrier Types
  • Newborn Screening of SMA
  • Pilot NBS Study Results
  • Mechanism of Action for SMA Therapies
  • Nusinersen Clinical Trial Data
  • Onasemnogene Clinical Trial Data
  • Risdiplam Clinical Trial Data

Faculty

Claudia A. Chiriboga, MD, MPH
Professor of Neurology and Pediatrics
Columbia University
New York, NY


Julie Parsons, MD
Co-Director of the Neuromuscular Clinic
Professor of Clinical Pediatrics and Neurology
Children’s Hospital Colorado
Aurora, CO


Perry Shieh, MD, PhD
Professor of Neurology
UCLA Medical Center
Los Angeles, CA


MOC Peer Reviewers

Gyula Acsadi, MD, PhD
Division Head, Neurology
Connecticut Children’s Hospital

Theodore O. Bruno, MD
Chief Medical Officer
The France Foundation

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures:

  • Dr. Claudia A. Chiriboga receives funding support from AveXis, Biogen, NIH, Roche, and SMA Foundation. She is also on the advisory board for AveXis, Cytokinetics, Genentech, PTC Therapeutics, and Roche.
  • Dr. Julie Parsons does contract research for AveXis, Biogen, Scholar Rock, and PTC Therapeutics.
  • Dr. Perry Shieh is a consultant for AveXis, Biogen, Genentech, Sarepta, and PTC Therapeutics. He serves on the speakers bureau for Alexion, AveXis, Biogen, CSL Behring, Genentech, and Grifols.

MOC Reviewer Disclosures:

  • Dr. Theodore O. Bruno reports that his spouse is employed by Allergan.
  • Dr. Gyula Acsadi has no relevant financial relationships to report.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity.
  4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
  6. Credit documentation/reporting:

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Part II points
Released: December 1, 2020
Expires: November 30, 2021
60 minutes to complete

Accredited By

Target Audience

This activity is intended for multidisciplinary groups of clinicians including neuromuscular specialists, pediatric neurologists, general neurologists, pediatricians, medical geneticists, genetic counselors, and other health care providers who are involved in the management of spinal muscular atrophy (SMA).

Learning Objectives

Upon completion of this course, the participants should be able to:

  • Review pathology, genetics, and epidemiology of SMA
  • Explain the importance of genetic testing for SMA
  • Discuss newborn screening and its importance in early diagnosis of SMA
  • Evaluate new and emerging therapies for SMA

Activity Description

With 3 therapies available for spinal muscular atrophy (SMA), clinicians need education in the genetics, newborn screening, and the clinical trial data. In these short videos, learners can choose the area they need education and hear from the experts.

Agenda

  • Presentation of SMA
  • Genetics of SMA
  • SMA Type and SMN2 Copy Number
  • Prevalence and Natural History of SMA
  • Diagnostic and Screening Algorithm
  • Genetic Testing for SMA
  • SMA Carrier Types
  • Newborn Screening of SMA
  • Pilot NBS Study Results
  • Mechanism of Action for SMA Therapies
  • Nusinersen Clinical Trial Data
  • Onasemnogene Clinical Trial Data
  • Risdiplam Clinical Trial Data

Faculty

Claudia A. Chiriboga, MD, MPH
Professor of Neurology and Pediatrics
Columbia University
New York, NY


Julie Parsons, MD
Co-Director of the Neuromuscular Clinic
Professor of Clinical Pediatrics and Neurology
Children’s Hospital Colorado
Aurora, CO


Perry Shieh, MD, PhD
Professor of Neurology
UCLA Medical Center
Los Angeles, CA


MOC Peer Reviewers

Gyula Acsadi, MD, PhD
Division Head, Neurology
Connecticut Children’s Hospital

Theodore O. Bruno, MD
Chief Medical Officer
The France Foundation

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures:

  • Dr. Claudia A. Chiriboga receives funding support from AveXis, Biogen, NIH, Roche, and SMA Foundation. She is also on the advisory board for AveXis, Cytokinetics, Genentech, PTC Therapeutics, and Roche.
  • Dr. Julie Parsons does contract research for AveXis, Biogen, Scholar Rock, and PTC Therapeutics.
  • Dr. Perry Shieh is a consultant for AveXis, Biogen, Genentech, Sarepta, and PTC Therapeutics. He serves on the speakers bureau for Alexion, AveXis, Biogen, CSL Behring, Genentech, and Grifols.

MOC Reviewer Disclosures:

  • Dr. Theodore O. Bruno reports that his spouse is employed by Allergan.
  • Dr. Gyula Acsadi has no relevant financial relationships to report.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity.
  4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
  6. Credit documentation/reporting:

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Neurology Presentations

1.00 AAPA / CME / CNE / CPE
Vindico
Therapeutic Advances in the Management of Relapsing Forms of Multiple Sclerosis

Therapeutic Advances in the Management of Relapsing Forms of Multiple Sclerosis

Start

Activity Details

Free CME, CNE, CPE, AAPA
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1.0 AAPA Category 1 CME credit(s)
Released: March 12, 2021
Expires: March 11, 2022
60 minutes to complete

Accredited By

Target Audience

The intended audience for this activity is neurologists, neurology nursing professionals, pharmacists, physician assistants, and other health care professionals involved in the management of patients with relapsing forms of multiple sclerosis (MS).

Learning Objectives

Upon successful completion of this activity, participants will be able to:

  • Identify patients with relapsing forms of multiple sclerosis (MS) who may benefit from existing therapies.
  • Examine the comparative mechanisms of action, methods of administration, pharmacological activity, efficacy, and tolerability of current and emerging treatment options for patients with relapsing forms of MS.
  • Evaluate the latest clinical evidence regarding new disease-modifying therapies for the management of patients with relapsing forms of MS.

Activity Description

Although rapid advances in the management of patients with multiple sclerosis (MS) are poised to improve patient outcomes, clinical decision-making has become more complex. There are numerous approved and emerging disease-modifying therapies (DMTs) for patients with relapsing forms of MS. Although most patients with MS present with the relapsing form, a staggering 80% go on to develop secondary progressive MS, the course associated with progressive worsening of neurologic function. The expanded pool of DMTs has changed the clinical approach to therapy. Whereas the ability of a therapy to reduce the relapse rate or disability progression has historically driven DMT selection, the emergence of new therapeutic options combined with the longevity and variable disease course of MS necessitates consideration of additional factors, such as safety, convenience, and management of comorbidities. In this continuing educational activity, expert clinicians discuss the latest updates in therapies for MS.

Agenda

Introduction
Patricia K. Coyle, MD, FAAN, FANA

Identifying Relapsing Forms of Multiple Sclerosis: Differentiation of Phenotypes
Patricia Melville, MSN, NP-C, MSCN

Panel Discussion
Moderated by Patricia K. Coyle, MD, FAAN, FANA

Treating Relapsing Forms of Multiple Sclerosis: Comparing Current and Emerging Agents
Clyde E. Markowitz, MD

Panel Discussion
Moderated by Patricia K. Coyle, MD, FAAN, FANA

Applying the Latest Evidence: Clinical Implications
Patricia K. Coyle, MD, FAAN, FANA

Panel Discussion
Moderated by Patricia K. Coyle, MD, FAAN, FANA

Conclusion
Patricia K. Coyle, MD, FAAN, FANA

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director, Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Novartis, Sanofi Genzyme, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech, MedDay, NINDS, Novartis

Faculty

Clyde E. Markowitz, MD
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Disclosures:
Consulting Fee: Actelion, Alexion, Bayer, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Janssen, Novartis, Sanofi Genzyme, Teva


Patricia Melville, MSN, NP-C, MSCN
Clinical Instructor
Stony Brook MS Comprehensive Care Center
State University of New York
Stony Brook, NY

Disclosures:
Consulting Fee: Biogen, Bristol Myers Squibb, EMD Serono, Novartis, Genentech, Sanofi Genzyme
Speakers Bureau: Alexion, Biogen, Bristol Myers Squibb, EMD Serono, Novartis, Sanofi Genzyme
Contracted Research: Biogen, Corrona, Genentech, Johnson & Johnson, MedDay, Novartis

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education, American Nurses Credentialing Center’s Commission on Accreditation, Accreditation Council for Pharmacy Education, and American Academy of Physician Assistants’ Standards for Integrity and Independence in Accredited Continuing Education, all accredited providers are required to identify, mitigate and disclose to the activity audience the financial relationships with ineligible companies of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 24 months with an ineligible company and manage those relationships such that there is no presence of commercial bias in the education. Relationship information is accurate at the time of content development.

Planners/Reviewers
June Halper, MSN, APN-C, MSCN, FAAN, and Laurie Scudder, DNP, NP, served as planners and reviewers and have declared that they have no relevant financial relationships to disclose.

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI,CHCP, served as planner and reviewer and has declared that he has no relevant financial relationships to disclose.

The Consortium of Multiple Sclerosis Centers Staff
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at The Consortium of Multiple Sclerosis Centers and Vindico Medical Education, Offices of Medical Affairs and Compliance.

Accreditation Statement

The Consortium of Multiple Sclerosis Centers is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Consortium of Multiple Sclerosis Centers is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

The Consortium of Multiple Sclerosis Centers has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria.

Designation of Credit

The Consortium of Multiple Sclerosis Centers designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Consortium of Multiple Sclerosis Centers will provide a maximum of 1.0 contact hour(s) for nurses.

This program is acceptable for 1.0 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-9999-21-002-H01-P, effective 3/12/21. This is a knowledge-based activity, and there is no fee to attend.

This activity is designated for 1.0 AAPA Category 1 CME credit(s). Approval is valid until March 11, 2022. PAs should only claim credit commensurate with the extent of their participation.

This enduring material is approved for 1 year from the date of original release, March 12, 2021 to March 11, 2022.

Instructions for Receiving Credit

To participate in this CE activity, you must read the learning objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, The Consortium of Multiple Sclerosis Centers will issue an AMA PRA Category 1 Credit(s)™ Certificate, Learner Paced Contact Hour(s) Certificate, or AAPA Category 1 CME Certificate or Vindico Medical Education will issue a CPE statement of credit. Pharmacist learners who submit their NABP and DOB will be reported to the CPE Monitor by Vindico Medical Education directly.

Statement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of The Consortium of Multiple Sclerosis Centers and Vindico Medical Education continuing education activities does not necessarily reflect the views and opinions of The Consortium of Multiple Sclerosis Centers and Vindico Medical Education. Neither The Consortium of Multiple Sclerosis Centers, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

CME/CNE/AAPA Questions?
Contact us at education@mscare.org

CPE Questions?
Contact us at CME@VindicoCME.com

Activity Details

Free CME, CNE, CPE, AAPA
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1.0 AAPA Category 1 CME credit(s)
Released: March 12, 2021
Expires: March 11, 2022
60 minutes to complete

Accredited By

Target Audience

The intended audience for this activity is neurologists, neurology nursing professionals, pharmacists, physician assistants, and other health care professionals involved in the management of patients with relapsing forms of multiple sclerosis (MS).

Learning Objectives

Upon successful completion of this activity, participants will be able to:

  • Identify patients with relapsing forms of multiple sclerosis (MS) who may benefit from existing therapies.
  • Examine the comparative mechanisms of action, methods of administration, pharmacological activity, efficacy, and tolerability of current and emerging treatment options for patients with relapsing forms of MS.
  • Evaluate the latest clinical evidence regarding new disease-modifying therapies for the management of patients with relapsing forms of MS.

Activity Description

Although rapid advances in the management of patients with multiple sclerosis (MS) are poised to improve patient outcomes, clinical decision-making has become more complex. There are numerous approved and emerging disease-modifying therapies (DMTs) for patients with relapsing forms of MS. Although most patients with MS present with the relapsing form, a staggering 80% go on to develop secondary progressive MS, the course associated with progressive worsening of neurologic function. The expanded pool of DMTs has changed the clinical approach to therapy. Whereas the ability of a therapy to reduce the relapse rate or disability progression has historically driven DMT selection, the emergence of new therapeutic options combined with the longevity and variable disease course of MS necessitates consideration of additional factors, such as safety, convenience, and management of comorbidities. In this continuing educational activity, expert clinicians discuss the latest updates in therapies for MS.

Agenda

Introduction
Patricia K. Coyle, MD, FAAN, FANA

Identifying Relapsing Forms of Multiple Sclerosis: Differentiation of Phenotypes
Patricia Melville, MSN, NP-C, MSCN

Panel Discussion
Moderated by Patricia K. Coyle, MD, FAAN, FANA

Treating Relapsing Forms of Multiple Sclerosis: Comparing Current and Emerging Agents
Clyde E. Markowitz, MD

Panel Discussion
Moderated by Patricia K. Coyle, MD, FAAN, FANA

Applying the Latest Evidence: Clinical Implications
Patricia K. Coyle, MD, FAAN, FANA

Panel Discussion
Moderated by Patricia K. Coyle, MD, FAAN, FANA

Conclusion
Patricia K. Coyle, MD, FAAN, FANA

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director, Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Novartis, Sanofi Genzyme, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech, MedDay, NINDS, Novartis

Faculty

Clyde E. Markowitz, MD
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Disclosures:
Consulting Fee: Actelion, Alexion, Bayer, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Janssen, Novartis, Sanofi Genzyme, Teva


Patricia Melville, MSN, NP-C, MSCN
Clinical Instructor
Stony Brook MS Comprehensive Care Center
State University of New York
Stony Brook, NY

Disclosures:
Consulting Fee: Biogen, Bristol Myers Squibb, EMD Serono, Novartis, Genentech, Sanofi Genzyme
Speakers Bureau: Alexion, Biogen, Bristol Myers Squibb, EMD Serono, Novartis, Sanofi Genzyme
Contracted Research: Biogen, Corrona, Genentech, Johnson & Johnson, MedDay, Novartis

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education, American Nurses Credentialing Center’s Commission on Accreditation, Accreditation Council for Pharmacy Education, and American Academy of Physician Assistants’ Standards for Integrity and Independence in Accredited Continuing Education, all accredited providers are required to identify, mitigate and disclose to the activity audience the financial relationships with ineligible companies of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 24 months with an ineligible company and manage those relationships such that there is no presence of commercial bias in the education. Relationship information is accurate at the time of content development.

Planners/Reviewers
June Halper, MSN, APN-C, MSCN, FAAN, and Laurie Scudder, DNP, NP, served as planners and reviewers and have declared that they have no relevant financial relationships to disclose.

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI,CHCP, served as planner and reviewer and has declared that he has no relevant financial relationships to disclose.

The Consortium of Multiple Sclerosis Centers Staff
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at The Consortium of Multiple Sclerosis Centers and Vindico Medical Education, Offices of Medical Affairs and Compliance.

Accreditation Statement

The Consortium of Multiple Sclerosis Centers is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Consortium of Multiple Sclerosis Centers is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

The Consortium of Multiple Sclerosis Centers has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria.

Designation of Credit

The Consortium of Multiple Sclerosis Centers designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Consortium of Multiple Sclerosis Centers will provide a maximum of 1.0 contact hour(s) for nurses.

This program is acceptable for 1.0 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-9999-21-002-H01-P, effective 3/12/21. This is a knowledge-based activity, and there is no fee to attend.

This activity is designated for 1.0 AAPA Category 1 CME credit(s). Approval is valid until March 11, 2022. PAs should only claim credit commensurate with the extent of their participation.

This enduring material is approved for 1 year from the date of original release, March 12, 2021 to March 11, 2022.

Instructions for Receiving Credit

To participate in this CE activity, you must read the learning objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, The Consortium of Multiple Sclerosis Centers will issue an AMA PRA Category 1 Credit(s)™ Certificate, Learner Paced Contact Hour(s) Certificate, or AAPA Category 1 CME Certificate or Vindico Medical Education will issue a CPE statement of credit. Pharmacist learners who submit their NABP and DOB will be reported to the CPE Monitor by Vindico Medical Education directly.

Statement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of The Consortium of Multiple Sclerosis Centers and Vindico Medical Education continuing education activities does not necessarily reflect the views and opinions of The Consortium of Multiple Sclerosis Centers and Vindico Medical Education. Neither The Consortium of Multiple Sclerosis Centers, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

CME/CNE/AAPA Questions?
Contact us at education@mscare.org

CPE Questions?
Contact us at CME@VindicoCME.com

1.00 CME / MOC
Vindico
Seeking a Cure for Alzheimer’s Disease: Is There Hope?

Seeking a Cure for Alzheimer’s Disease: Is There Hope?

Start

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)
ABIM MOC Points
Released: February 28, 2021
Expires: February 27, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, psychiatrists, primary care physicians, geriatric physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the current understanding of the pathophysiology of Alzheimer’s disease (AD) and the latest evidence-based strategies and modalities for the early and accurate diagnosis of patients with AD.
  • Review the mechanisms of action, clinical endpoints, and latest clinical evidence regarding new and emerging agents for the treatment of patients with AD.
  • Assess the role of multidisciplinary collaborative care models for the management of patients with AD.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related, neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. Current therapies delay cognitive decline in some patients, but they do not treat the underlying causes of the disease nor do they halt the progression of the disease. Despite the significant burden on patients, there remains no approved disease-modifying therapy to treat patients with AD. In this program, expert faculty will provide guidance on the mechanisms of action, clinical endpoints, and latest clinical evidence regarding new and emerging agents for the treatment of patients with AD. They will also discuss the current understanding of the pathophysiology of AD; the latest evidence-based strategies for an early and accurate diagnosis; as well as the role of multidisciplinary, collaborative-care models for the management of patients with AD.

Agenda

Introduction
Marwan Noel Sabbagh, MD, FAAN, CCRI

Critical Importance of Early Diagnosis
Sharon Cohen, MD, FRCPC

Panel Discussion

Current and Emerging Therapies for Alzheimer’s Disease
Anton P. Porsteinsson, MD

Panel Discussion

Collaborative Care Models for Alzheimer’s Disease
Marwan Noel Sabbagh, MD, FAAN, CCRI

Panel Discussion and Conclusion

Activity Chair

Marwan Noel Sabbagh, MD, FAAN, CCRI
Director, Lou Ruvo Center for Brain Health – Cleveland Clinic Nevada
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic
Lerner College of Medicine of Case Western Reserve University
Clinical Professor, Department of Neurology, UNLV
Las Vegas, NV

Disclosure:
Consulting Fee: Alzheon, Athira, Biogen, Cortexyme, Danone, Eisai, Neurotrope, Regeneron, Roche-Genentech, Stage 2 Innovations, vTv Therapeutics
Contracted Research: Keep Memory Alive Foundation, National Institute on Aging
Ownership Interest: Brain Health Inc., NeuroReserve, NeuroTau, Neurotrope, Optimal Cognitive Health Company, uMETHOD Health, Versanum

Faculty

Anton P. Porsteinsson, MD
William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine
Director, Alzheimer's Disease Care, Research and Education Program (AD-CARE)
Rochester, NY

Disclosure:
Consulting Fee: Acadia, Avanir, Biogen, Cadent Therapeutics, Functional Neuromodulation, MapLight Therapeutics, Premier Healthcare Solutions, Sunovion, Syneos
Contracted Research: Alector, Athira, Avanir, Biogen, Biohaven, Eisai, Eli Lilly, Genentech/Roche, Vaccinex
Scientific Advisory Board: Alzheon


Sharon Cohen, MD, FRCPC
Medical Director and Principal Investigator
Toronto Memory Program
Toronto, Canada

Disclosure:
Consulting Fee: Alnylam, Biogen, Cogstate, ProMIS Neurosciences, RetiSpec
Contracted Research: AbbVie, AgeneBio, Alector, Anavex, Biogen, CCHI, Eisai, Genentech, Janssen, Lilly, RetiSpec, Roche, Vielight


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)
ABIM MOC Points
Released: February 28, 2021
Expires: February 27, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, psychiatrists, primary care physicians, geriatric physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the current understanding of the pathophysiology of Alzheimer’s disease (AD) and the latest evidence-based strategies and modalities for the early and accurate diagnosis of patients with AD.
  • Review the mechanisms of action, clinical endpoints, and latest clinical evidence regarding new and emerging agents for the treatment of patients with AD.
  • Assess the role of multidisciplinary collaborative care models for the management of patients with AD.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related, neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. Current therapies delay cognitive decline in some patients, but they do not treat the underlying causes of the disease nor do they halt the progression of the disease. Despite the significant burden on patients, there remains no approved disease-modifying therapy to treat patients with AD. In this program, expert faculty will provide guidance on the mechanisms of action, clinical endpoints, and latest clinical evidence regarding new and emerging agents for the treatment of patients with AD. They will also discuss the current understanding of the pathophysiology of AD; the latest evidence-based strategies for an early and accurate diagnosis; as well as the role of multidisciplinary, collaborative-care models for the management of patients with AD.

Agenda

Introduction
Marwan Noel Sabbagh, MD, FAAN, CCRI

Critical Importance of Early Diagnosis
Sharon Cohen, MD, FRCPC

Panel Discussion

Current and Emerging Therapies for Alzheimer’s Disease
Anton P. Porsteinsson, MD

Panel Discussion

Collaborative Care Models for Alzheimer’s Disease
Marwan Noel Sabbagh, MD, FAAN, CCRI

Panel Discussion and Conclusion

Activity Chair

Marwan Noel Sabbagh, MD, FAAN, CCRI
Director, Lou Ruvo Center for Brain Health – Cleveland Clinic Nevada
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic
Lerner College of Medicine of Case Western Reserve University
Clinical Professor, Department of Neurology, UNLV
Las Vegas, NV

Disclosure:
Consulting Fee: Alzheon, Athira, Biogen, Cortexyme, Danone, Eisai, Neurotrope, Regeneron, Roche-Genentech, Stage 2 Innovations, vTv Therapeutics
Contracted Research: Keep Memory Alive Foundation, National Institute on Aging
Ownership Interest: Brain Health Inc., NeuroReserve, NeuroTau, Neurotrope, Optimal Cognitive Health Company, uMETHOD Health, Versanum

Faculty

Anton P. Porsteinsson, MD
William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine
Director, Alzheimer's Disease Care, Research and Education Program (AD-CARE)
Rochester, NY

Disclosure:
Consulting Fee: Acadia, Avanir, Biogen, Cadent Therapeutics, Functional Neuromodulation, MapLight Therapeutics, Premier Healthcare Solutions, Sunovion, Syneos
Contracted Research: Alector, Athira, Avanir, Biogen, Biohaven, Eisai, Eli Lilly, Genentech/Roche, Vaccinex
Scientific Advisory Board: Alzheon


Sharon Cohen, MD, FRCPC
Medical Director and Principal Investigator
Toronto Memory Program
Toronto, Canada

Disclosure:
Consulting Fee: Alnylam, Biogen, Cogstate, ProMIS Neurosciences, RetiSpec
Contracted Research: AbbVie, AgeneBio, Alector, Anavex, Biogen, CCHI, Eisai, Genentech, Janssen, Lilly, RetiSpec, Roche, Vielight


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / CNE
Vindico
Multiple Sclerosis in Women: Adaptation of Management Strategies for Family Planning and Beyond–Multiple Sclerosis in the Postpartum Period: Lactation and Treatment Considerations

Multiple Sclerosis in Women: Adaptation of Management Strategies for Family Planning and Beyond–Multiple Sclerosis in the Postpartum Period: Lactation and Treatment Considerations

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: February 28, 2021
Expires: February 27, 2022
15 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objective

Upon successful completion of the activity, participants should be better able to:

  • Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.

Activity Description

In this Curbside Consult, Drs. Patricia Coyle and Clyde Markowitz will discuss latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with multiple sclerosis during postpartum/lactation.

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis

Faculty

Clyde E. Markowitz, MD
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Disclosures:
Consulting Fee: Actelion, Alexion, Bayer, Biogen, Celgene/Bristol Myers Squibb, EMD Serono, Genentech/Roche, Janssen, Novartis, Sanofi/Genzyme, Teva

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Viela Bio

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: February 28, 2021
Expires: February 27, 2022
15 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objective

Upon successful completion of the activity, participants should be better able to:

  • Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.

Activity Description

In this Curbside Consult, Drs. Patricia Coyle and Clyde Markowitz will discuss latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with multiple sclerosis during postpartum/lactation.

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis

Faculty

Clyde E. Markowitz, MD
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Disclosures:
Consulting Fee: Actelion, Alexion, Bayer, Biogen, Celgene/Bristol Myers Squibb, EMD Serono, Genentech/Roche, Janssen, Novartis, Sanofi/Genzyme, Teva

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Viela Bio

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / CNE
Vindico
Multiple Sclerosis in Women: Adaptation of Management Strategies for Family Planning and Beyond–Multiple Sclerosis During Pregnancy: Charting the Disease Course

Multiple Sclerosis in Women: Adaptation of Management Strategies for Family Planning and Beyond–Multiple Sclerosis During Pregnancy: Charting the Disease Course

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: February 28, 2021
Expires: February 27, 2022
15 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate understanding of protective effects of pregnancy in women with MS, including the marked changes in disease activity during the 3 trimesters.
  • Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.

Activity Description

In this Curbside Consult, Drs. Patricia Coyle and Maria K. Houtchens will discuss the effects of pregnancy in women with multiple sclerosis, as well as the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in pregnant women with MS.

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis

Faculty

Maria K. Houtchens, MD, MMs
Associate Professor of Neurology
Harvard Medical School
Director, Clinical Care
Director, Women’s Health Program
Brigham and Women’s Hospital
Boston, MA

Disclosures:
Consulting Fee: Biogen, EMD Serono, Novartis, Roche, Sanofi Genzyme
Contracted Research: Biogen, EMD Serono, Roche, Sanofi Genzyme

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Viela Bio

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: February 28, 2021
Expires: February 27, 2022
15 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate understanding of protective effects of pregnancy in women with MS, including the marked changes in disease activity during the 3 trimesters.
  • Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.

Activity Description

In this Curbside Consult, Drs. Patricia Coyle and Maria K. Houtchens will discuss the effects of pregnancy in women with multiple sclerosis, as well as the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in pregnant women with MS.

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis

Faculty

Maria K. Houtchens, MD, MMs
Associate Professor of Neurology
Harvard Medical School
Director, Clinical Care
Director, Women’s Health Program
Brigham and Women’s Hospital
Boston, MA

Disclosures:
Consulting Fee: Biogen, EMD Serono, Novartis, Roche, Sanofi Genzyme
Contracted Research: Biogen, EMD Serono, Roche, Sanofi Genzyme

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Viela Bio

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.50 CME
Postgraduate Institute for Medicine
From Critique to Consensus: Quantifying and Clarifying Expert Perspectives on the Future Management of Alzheimer’s Disease (AD) – Part 3: Tools for Diagnostic and Monitoring Strategies in the Future Management of AD

From Critique to Consensus: Quantifying and Clarifying Expert Perspectives on the Future Management of Alzheimer’s Disease (AD) – Part 3: Tools for Diagnostic and Monitoring Strategies in the Future Management of AD

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 4, 2021
Expires: February 4, 2022
30 minutes to complete

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

Recognize the role of existing and emerging biomarkers in the categorization and monitoring of AD and use this information to identify how this could be implemented in future AD management should such tools become more accessible.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 3 will focus on the role of biomarkers in AD diagnosis and monitoring as well as the expanded need for these methods should a disease-specific therapy be approved.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the third of this three-part series, Drs. Sabbagh, Smith, and Isaacson will outline the biomarkers that they currently use in AD management alongside their projected changes to standard clinical practices should disease-specific therapies become available. They will also discuss the emergence of novel serum biomarker tests and the potential importance they may develop in the coming years.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.


Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis


Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.


Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 4, 2021
Expires: February 4, 2022
30 minutes to complete

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

Recognize the role of existing and emerging biomarkers in the categorization and monitoring of AD and use this information to identify how this could be implemented in future AD management should such tools become more accessible.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 3 will focus on the role of biomarkers in AD diagnosis and monitoring as well as the expanded need for these methods should a disease-specific therapy be approved.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the third of this three-part series, Drs. Sabbagh, Smith, and Isaacson will outline the biomarkers that they currently use in AD management alongside their projected changes to standard clinical practices should disease-specific therapies become available. They will also discuss the emergence of novel serum biomarker tests and the potential importance they may develop in the coming years.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.


Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis


Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.


Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.

0.75 CME
Postgraduate Institute for Medicine
From Critique to Consensus: Quantifying and Clarifying Expert Perspectives on the Future Management of Alzheimer’s Disease (AD) – Part 2: Current Treatments and Rising Phase 3 Disease-Modifying Therapies

From Critique to Consensus: Quantifying and Clarifying Expert Perspectives on the Future Management of Alzheimer’s Disease (AD) – Part 2: Current Treatments and Rising Phase 3 Disease-Modifying Therapies

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: February 4, 2021
Expires: February 4, 2022
45 minutes to complete

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

  1. Assess patient factors that may affect eligibility for treatment with amyloid-targeted disease modifying therapies (DMTs) to determine for which patients this strategy holds the most promise if approved.
  2. Evaluate expert opinions of and available Phase 2/3 data with amyloid-targeting DMTs to assess their potential role in future patient management.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 2 will focus on the treatments currently available for AD contrasted with the rising agents that have the potential to enter the treatment armamentarium in the near future.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the second of this three-part series, Drs. Sabbagh, Smith, and Isaacson will discuss the use and limitations of currently available AD therapies as well as the potential role of rising, disease-specific therapies that are on the horizon.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.


Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis


Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.


Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: February 4, 2021
Expires: February 4, 2022
45 minutes to complete

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

  1. Assess patient factors that may affect eligibility for treatment with amyloid-targeted disease modifying therapies (DMTs) to determine for which patients this strategy holds the most promise if approved.
  2. Evaluate expert opinions of and available Phase 2/3 data with amyloid-targeting DMTs to assess their potential role in future patient management.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 2 will focus on the treatments currently available for AD contrasted with the rising agents that have the potential to enter the treatment armamentarium in the near future.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the second of this three-part series, Drs. Sabbagh, Smith, and Isaacson will discuss the use and limitations of currently available AD therapies as well as the potential role of rising, disease-specific therapies that are on the horizon.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.


Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis


Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.


Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.

0.50 CME
Postgraduate Institute for Medicine
From Critique to Consensus: Quantifying and Clarifying Expert Perspectives on the Future Management of Alzheimer’s Disease (AD) – Part 1: Evolving Understanding of Pathophysiology and Proposed Framework of AD

From Critique to Consensus: Quantifying and Clarifying Expert Perspectives on the Future Management of Alzheimer’s Disease (AD) – Part 1: Evolving Understanding of Pathophysiology and Proposed Framework of AD

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 4, 2021
Expires: February 4, 2022
30 minutes to complete

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

  1. Assess the fundamental principles and current status of the amyloid hypothesis—including historical obstacles associated with evaluating amyloid targeting disease modifying therapies (DMTs)—to appraise its potential utility and limitations in guiding AD diagnostic and clinical strategy.
  2. Identify the potential utility of a biomarker-based approach to AD management in order to understand how such strategies may be integrated into practice in the event that targeted therapies become available.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 1 will focus on the way our understanding of AD pathophysiology has evolved and the most widely held viewpoints among modern dementia specialists.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the first of this three-part series, Drs. Sabbagh, Smith, and Isaacson will review the traditional theories of the path to AD as well as their own personal takes on modern advancements in its understanding. They will also discuss how the historical mystery of AD has contributed to the widespread failures in pharmaceutical development and why these failures may provide more insight than may be apparent at the surface.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.


Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis


Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.


Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 4, 2021
Expires: February 4, 2022
30 minutes to complete

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

  1. Assess the fundamental principles and current status of the amyloid hypothesis—including historical obstacles associated with evaluating amyloid targeting disease modifying therapies (DMTs)—to appraise its potential utility and limitations in guiding AD diagnostic and clinical strategy.
  2. Identify the potential utility of a biomarker-based approach to AD management in order to understand how such strategies may be integrated into practice in the event that targeted therapies become available.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 1 will focus on the way our understanding of AD pathophysiology has evolved and the most widely held viewpoints among modern dementia specialists.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the first of this three-part series, Drs. Sabbagh, Smith, and Isaacson will review the traditional theories of the path to AD as well as their own personal takes on modern advancements in its understanding. They will also discuss how the historical mystery of AD has contributed to the widespread failures in pharmaceutical development and why these failures may provide more insight than may be apparent at the surface.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.


Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis


Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.


Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.

0.50 CME / MOC
AKH Inc., Advancing Knowledge in Healthcare
Ensuring Best Practices in Spinal Muscular Atrophy Management

Ensuring Best Practices in Spinal Muscular Atrophy Management

Start

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)™/ABIM MOC Points
Released: January 6, 2021
Expires: January 5, 2022
30 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Neurology clinicians who diagnose and manage spinal muscular atrophy (SMA) in patients.

Learning Objectives

After completing this activity, the clinician should be able to:

  • Describe the expected impact of newborn screening on the early commencement of treatment in patients with spinal muscular atrophy (SMA)
  • Employ available efficacy, safety, and tolerability data on disease-modifying treatments in pre-symptomatic and symptomatic patients with SMA
  • Apply established symptomatic and supportive care strategies in patients with SMA throughout the course of their disease

Activity Description

In this activity, a panel of experts in spinal muscular atrophy (SMA) use a series of case vignettes and clinical reflection points to emphasize the importance of early diagnosis and treatment of patients with pre-symptomatic, infantile-onset, and late-onset SMA.

Faculty

Diana P. Castro, MD (Chair)
Associate Professor, Pediatrics and Neurology
University of Texas Southwestern
Children’s Health
Dallas, TX

John Brandsema, MD
Child Neurologist and Neuromuscular Section Head
Children’s Hospital of Philadelphia
Assistant Professor, Clinical Neurology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Crystal M. Proud, MD
Neuromuscular Neurologist  
Children's Hospital of The King's Daughters
Norfolk, VA

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Diana P. Castro, MD, has affiliations with Biogen, PTC Therapeutics, ReveraGen BioPharma, Inc., Sarepta Therapeutics, Scholar Rock (Contracted Research).

John Brandsema, MD, has affiliations with AveXis, Biogen (Speakers Bureau); Audentes, AveXis, Biogen, Cytokinetics, Genentech, Momenta, NS Pharma, PTC Therapeutics, Sarepta Therapeutics, WaVe (Consulting Fees); Alexion, AveXis, Biogen, CSL Behring, Cytokinetics, Fibrogen, Pfizer, PTC Therapeutics, Sarepta Therapeutics, Summit, WaVe (Contracted Research).

Crystal M. Proud, MD, has affiliations with AveXis, Biogen (Speakers Bureau); AveXis, Biogen (Consulting Fees); AveXis, Biogen (Contracted Research).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations, has no financial relationships to disclose.

RMEI Medical Education, LLC
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.
The RMEI Medical Education planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Declaration
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points and 0 patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must complete the following steps
Step 1: Review and successfully complete the activity
Step 2: Proceed to the evaluation and provide your ABIM ID and date of birth
Step 3: MOC points will be submitted to ABIM profiles within 6-8 weeks of completion

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation form and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)™/ABIM MOC Points
Released: January 6, 2021
Expires: January 5, 2022
30 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Neurology clinicians who diagnose and manage spinal muscular atrophy (SMA) in patients.

Learning Objectives

After completing this activity, the clinician should be able to:

  • Describe the expected impact of newborn screening on the early commencement of treatment in patients with spinal muscular atrophy (SMA)
  • Employ available efficacy, safety, and tolerability data on disease-modifying treatments in pre-symptomatic and symptomatic patients with SMA
  • Apply established symptomatic and supportive care strategies in patients with SMA throughout the course of their disease

Activity Description

In this activity, a panel of experts in spinal muscular atrophy (SMA) use a series of case vignettes and clinical reflection points to emphasize the importance of early diagnosis and treatment of patients with pre-symptomatic, infantile-onset, and late-onset SMA.

Faculty

Diana P. Castro, MD (Chair)
Associate Professor, Pediatrics and Neurology
University of Texas Southwestern
Children’s Health
Dallas, TX

John Brandsema, MD
Child Neurologist and Neuromuscular Section Head
Children’s Hospital of Philadelphia
Assistant Professor, Clinical Neurology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Crystal M. Proud, MD
Neuromuscular Neurologist  
Children's Hospital of The King's Daughters
Norfolk, VA

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Diana P. Castro, MD, has affiliations with Biogen, PTC Therapeutics, ReveraGen BioPharma, Inc., Sarepta Therapeutics, Scholar Rock (Contracted Research).

John Brandsema, MD, has affiliations with AveXis, Biogen (Speakers Bureau); Audentes, AveXis, Biogen, Cytokinetics, Genentech, Momenta, NS Pharma, PTC Therapeutics, Sarepta Therapeutics, WaVe (Consulting Fees); Alexion, AveXis, Biogen, CSL Behring, Cytokinetics, Fibrogen, Pfizer, PTC Therapeutics, Sarepta Therapeutics, Summit, WaVe (Contracted Research).

Crystal M. Proud, MD, has affiliations with AveXis, Biogen (Speakers Bureau); AveXis, Biogen (Consulting Fees); AveXis, Biogen (Contracted Research).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations, has no financial relationships to disclose.

RMEI Medical Education, LLC
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.
The RMEI Medical Education planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Declaration
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points and 0 patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must complete the following steps
Step 1: Review and successfully complete the activity
Step 2: Proceed to the evaluation and provide your ABIM ID and date of birth
Step 3: MOC points will be submitted to ABIM profiles within 6-8 weeks of completion

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation form and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

0.25 CME / MOC
Vindico
Alzheimer’s Disease: Early Identification and Future Therapeutic Landscape—The Future Treatment Landscape of Alzheimer’s Disease With Drs. Raymond Scott Turner and Marwan Noel Sabbagh

Alzheimer’s Disease: Early Identification and Future Therapeutic Landscape—The Future Treatment Landscape of Alzheimer’s Disease With Drs. Raymond Scott Turner and Marwan Noel Sabbagh

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/ ABIM MOC
Released: December 31, 2020
Expires: December 30, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, primary care physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to evaluate the future treatment landscape to plan for effective patient identification and management.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. More than 5 million Americans are living with AD, which accounts for 60% to 80% of all dementia. By 2050, the number of Americans living with AD is projected to rise to 14 million. Despite this significant burden, currently approved AD treatments are symptomatic drugs that do not stop or delay disease progression, with no approved disease-modifying therapy. The latest data from emerging AD treatments suggest that early identification of AD patients is critical for optimizing outcomes. Thus, neurologists, primary care physicians, and other providers who care for these patients need education on strategies for the early identification and management of patients with AD. In this podcast, expert clinicians will discuss the future of treating Alzheimer’s disease by examining the mechanisms of action and clinical trial data of emerging agents.

Activity Chair

Raymond Scott Turner, PhD, MD, FAAN, FANA
Professor of Neurology
Georgetown University
Washington, DC

Disclosure:
Consulting Fee: Re:Cognition


Faculty

Marwan Noel Sabbagh, MD, FAAN, CCRI
Director, Lou Ruvo Center for Brain Health – Cleveland Clinic Nevada
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Clinical Professor, Department of Neurology, UNLV
Las Vegas, NV

Disclosure:
Consulting Fee: Alzheon, Athira, Biogen, Cortexyme, Danone, Eisai, Neurotrope, Regeneron, Roche-Genentech, Stage 2 Innovations, vTv Therapeutics
Contracted Research: Keep Memory Alive Foundation, National Institute of Aging
Ownership Interest: Brain Health Inc., NeuroReserve, NeuroTau, Neurotrope, Optimal Cognitive Health Company, uMethod Health, Versanum


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, listen to the podcast, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/ ABIM MOC
Released: December 31, 2020
Expires: December 30, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, primary care physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to evaluate the future treatment landscape to plan for effective patient identification and management.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. More than 5 million Americans are living with AD, which accounts for 60% to 80% of all dementia. By 2050, the number of Americans living with AD is projected to rise to 14 million. Despite this significant burden, currently approved AD treatments are symptomatic drugs that do not stop or delay disease progression, with no approved disease-modifying therapy. The latest data from emerging AD treatments suggest that early identification of AD patients is critical for optimizing outcomes. Thus, neurologists, primary care physicians, and other providers who care for these patients need education on strategies for the early identification and management of patients with AD. In this podcast, expert clinicians will discuss the future of treating Alzheimer’s disease by examining the mechanisms of action and clinical trial data of emerging agents.

Activity Chair

Raymond Scott Turner, PhD, MD, FAAN, FANA
Professor of Neurology
Georgetown University
Washington, DC

Disclosure:
Consulting Fee: Re:Cognition


Faculty

Marwan Noel Sabbagh, MD, FAAN, CCRI
Director, Lou Ruvo Center for Brain Health – Cleveland Clinic Nevada
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Clinical Professor, Department of Neurology, UNLV
Las Vegas, NV

Disclosure:
Consulting Fee: Alzheon, Athira, Biogen, Cortexyme, Danone, Eisai, Neurotrope, Regeneron, Roche-Genentech, Stage 2 Innovations, vTv Therapeutics
Contracted Research: Keep Memory Alive Foundation, National Institute of Aging
Ownership Interest: Brain Health Inc., NeuroReserve, NeuroTau, Neurotrope, Optimal Cognitive Health Company, uMethod Health, Versanum


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, listen to the podcast, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / MOC
Vindico
Alzheimer’s Disease: Early Identification and Future Therapeutic Landscape—The Critical Importance of Early Diagnosis of Alzheimer’s Disease With Drs. Raymond Scott Turner and Sharon Cohen

Alzheimer’s Disease: Early Identification and Future Therapeutic Landscape—The Critical Importance of Early Diagnosis of Alzheimer’s Disease With Drs. Raymond Scott Turner and Sharon Cohen

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/ ABIM MOC
Released: December 31, 2020
Expires: December 30, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, primary care physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to review the critical importance of diagnosing patients in the early stages of AD including the latest evidence-based diagnostic strategies and modalities.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. More than 5 million Americans are living with AD, which accounts for 60% to 80% of all dementia. By 2050, the number of Americans living with AD is projected to rise to 14 million. Despite this significant burden, currently approved AD treatments are symptomatic drugs that do not stop or delay disease progression, with no approved disease-modifying therapy. The latest data from emerging AD treatments suggest that early identification of AD patients is critical for optimizing outcomes. Thus, neurologists, primary care physicians, and other providers who care for these patients need education on strategies for the early identification and management of patients with AD. In this podcast, expert clinicians will discuss why it is important to diagnose Alzheimer’s disease early and available assessment tools to make an early diagnosis.

Activity Chair

Raymond Scott Turner, PhD, MD, FAAN, FANA
Professor of Neurology
Georgetown University
Washington, DC

Disclosure:
Consulting Fee: Re:Cognition


Faculty

Sharon Cohen, MD, FRCPC
Medical Director and Principal Investigator, Toronto Memory Program
Toronto, Canada

Disclosure:
Consulting Fee: Alnylam, Biogen, Cogstate, ProMIS Neurosciences, RetiSpec
Contracted Research: AbbVie, AgeneBio, Alector, Anavex, Biogen, CCHI, Eisai, Genentech, Janssen, Lilly, RetiSpec, Roche, Vielight


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, listen to the podcast, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/ ABIM MOC
Released: December 31, 2020
Expires: December 30, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, primary care physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to review the critical importance of diagnosing patients in the early stages of AD including the latest evidence-based diagnostic strategies and modalities.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. More than 5 million Americans are living with AD, which accounts for 60% to 80% of all dementia. By 2050, the number of Americans living with AD is projected to rise to 14 million. Despite this significant burden, currently approved AD treatments are symptomatic drugs that do not stop or delay disease progression, with no approved disease-modifying therapy. The latest data from emerging AD treatments suggest that early identification of AD patients is critical for optimizing outcomes. Thus, neurologists, primary care physicians, and other providers who care for these patients need education on strategies for the early identification and management of patients with AD. In this podcast, expert clinicians will discuss why it is important to diagnose Alzheimer’s disease early and available assessment tools to make an early diagnosis.

Activity Chair

Raymond Scott Turner, PhD, MD, FAAN, FANA
Professor of Neurology
Georgetown University
Washington, DC

Disclosure:
Consulting Fee: Re:Cognition


Faculty

Sharon Cohen, MD, FRCPC
Medical Director and Principal Investigator, Toronto Memory Program
Toronto, Canada

Disclosure:
Consulting Fee: Alnylam, Biogen, Cogstate, ProMIS Neurosciences, RetiSpec
Contracted Research: AbbVie, AgeneBio, Alector, Anavex, Biogen, CCHI, Eisai, Genentech, Janssen, Lilly, RetiSpec, Roche, Vielight


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, listen to the podcast, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Pages